JP2024505226A5 - - Google Patents

Info

Publication number
JP2024505226A5
JP2024505226A5 JP2023546047A JP2023546047A JP2024505226A5 JP 2024505226 A5 JP2024505226 A5 JP 2024505226A5 JP 2023546047 A JP2023546047 A JP 2023546047A JP 2023546047 A JP2023546047 A JP 2023546047A JP 2024505226 A5 JP2024505226 A5 JP 2024505226A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
modified
modified oligonucleotides
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505226A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014231 external-priority patent/WO2022165122A1/en
Publication of JP2024505226A publication Critical patent/JP2024505226A/ja
Publication of JP2024505226A5 publication Critical patent/JP2024505226A5/ja
Pending legal-status Critical Current

Links

JP2023546047A 2021-01-29 2022-01-28 ハンチンチンを調節するための化合物及び方法 Pending JP2024505226A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163143686P 2021-01-29 2021-01-29
US63/143,686 2021-01-29
PCT/US2022/014231 WO2022165122A1 (en) 2021-01-29 2022-01-28 Compounds and methods for modulating huntingtin

Publications (2)

Publication Number Publication Date
JP2024505226A JP2024505226A (ja) 2024-02-05
JP2024505226A5 true JP2024505226A5 (https=) 2025-02-05

Family

ID=82653847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546047A Pending JP2024505226A (ja) 2021-01-29 2022-01-28 ハンチンチンを調節するための化合物及び方法

Country Status (11)

Country Link
US (1) US20240376469A1 (https=)
EP (1) EP4284504A4 (https=)
JP (1) JP2024505226A (https=)
KR (1) KR20230137958A (https=)
CN (1) CN116940683A (https=)
AU (1) AU2022213384A1 (https=)
CA (1) CA3210076A1 (https=)
IL (1) IL304218A (https=)
MX (1) MX2023008922A (https=)
TW (1) TW202241462A (https=)
WO (1) WO2022165122A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4423272A2 (en) * 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
IL326478A (en) * 2023-08-16 2026-04-01 Servier Lab Oligonucleotides for modulation of KCNT1 expression
EP4527927A1 (en) * 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105995A2 (en) * 2004-04-14 2005-11-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
NZ714887A (en) * 2009-09-11 2019-07-26 Ionis Pharmaceuticals Inc Modulation of huntingtin expression
CA2789038A1 (en) * 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
US8957040B2 (en) * 2010-02-08 2015-02-17 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
US10202599B2 (en) * 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US10533172B2 (en) * 2014-09-18 2020-01-14 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
US11674952B2 (en) * 2016-02-24 2023-06-13 The Rockefeller University Embryonic cell-based therapeutic candidate screening systems, models for Huntington's Disease and uses thereof
US12281305B2 (en) * 2018-11-21 2025-04-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing prion expression

Similar Documents

Publication Publication Date Title
JP2024505226A5 (https=)
JP2024079716A5 (https=)
US7572582B2 (en) Oligonucleotide analogues
US6794499B2 (en) Oligonucleotide analogues
JP5677716B2 (ja) オリゴヌクレオチド類似体を含むキット及び方法並びにオリゴヌクレオチド類似体の使用
CN1066456C (zh) 具有2'-醚基的寡核苷酸
JP2022526267A5 (https=)
US5672697A (en) Nucleoside 5'-methylene phosphonates
JP2021074021A5 (https=)
US9169256B2 (en) Artificial nucleic acids
JP2020022483A5 (https=)
PT98931B (pt) Processo para a ligacao de nucleosidos com uma ponte siloxano
CZ129197A3 (en) Nucleosides with modified sugar portion of a molecule and their use for preparing oligonucleotides
JP2022527105A5 (https=)
WO1997030064A1 (en) Hexitol containing oligonucleotides and their use in antisense strategies
JP2021522800A5 (https=)
JP2005500025A5 (https=)
JP2017518966A (ja) リン保護基ならびにそれらの調製方法および使用
JP3675847B2 (ja) ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法
JP2023524065A5 (https=)
JP2025511183A5 (https=)
JP2023549563A5 (https=)
Kolganova et al. Simple and Stereoselective Preparation of an 4‐(Aminomethyl)‐1, 2, 3‐triazolyl Nucleoside Phosphoramidite
JP4047814B2 (ja) 新規カリックス[4]アレーン−ヌクレオシドおよびカリックス[4]アレーン−オリゴヌクレオチドハイブリッド
JP4180681B2 (ja) アンチセンスオリゴヌクレオチド